This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Indiana University. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Innovations of Julia Azriel in Insulin Research
Introduction
Julia Azriel is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of insulin research, particularly through her innovative patent that focuses on single-chain insulin agonists. Her work aims to enhance the efficacy and specificity of insulin treatments for individuals with diabetes.
Latest Patents
Julia Azriel holds a patent for "Single-chain insulin agonists exhibiting high activity at the insulin receptor." This patent describes single-chain insulin analogs that demonstrate high potency and specificity for the insulin receptor. The invention involves optimally sized linking moieties that connect human insulin A and B chains, or their analogs and derivatives. Specifically, the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. One embodiment of the linking moiety includes a polyethylene glycol of 6-16 monomer units, while another embodiment features a non-native amino acid sequence derived from the IGF-1 C-peptide, comprising at least 8 and no more than 12 amino acids in length. Additionally, the patent discloses prodrug and conjugate derivatives of the single-chain insulin analogs.
Career Highlights
Julia Azriel is affiliated with Indiana University, where she continues her research and development in the field of insulin analogs. Her work has garnered attention for its potential to improve diabetes management through innovative insulin therapies.
Collaborations
Julia has collaborated with notable colleagues, including Richard Dennis DiMarchi and Zach Kaur, who have contributed to her research endeavors.
Conclusion
Julia Azriel's innovative work in insulin research exemplifies the impact of scientific advancements on diabetes treatment. Her patent for single-chain insulin agonists represents a significant step forward in the quest for more effective insulin therapies.